{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:44:28Z","timestamp":1776473068534,"version":"3.51.2"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan K.K.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo Company, Limited","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The objective of this analysis was to gain new insights into the patient characteristics and other factors associated with lasmiditan usage and clinical outcomes under conditions resembling the real-world setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a post hoc analysis of data from the 12-month, open-label extension (OLE) of the phase 3, double-blind, randomized, controlled CENTURION trial, which examined the efficacy and safety of lasmiditan as acute treatment across four migraine attacks. Patients completing the main study who treated\u2009\u2265\u20093 attacks could continue in the OLE. The initial lasmiditan dose was 100\u00a0mg, with dose adjustments to 50\u00a0mg or 200\u00a0mg allowed at the investigator\u2019s discretion. Patient and clinical characteristics were summarized by dosing pattern and completion status. Safety was assessed based on adverse event (AE) frequency by number of doses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 445 patients treated\u2009\u2265\u20091 migraine attacks with lasmiditan during the OLE, 321 of whom (72.1%) completed the study. Forty-seven percent of patients remained on the 100-mg initial dose during the OLE whereas 20.2% used both 100\u00a0mg and 50\u00a0mg, 30.6% used both 100\u00a0mg and 200\u00a0mg, and 6 (1.3%) used multiple dose levels. All dosing patterns were associated with clinical and patient-reported improvement; however, the 100-mg group had the highest proportion of patients reporting improvement in the Patient Global Impression of Change \u2013 Migraine Headache Condition (56.5% vs 33.4%\u201352.2%). In comparison, all three groups that made dose adjustments had higher rates of completion compared to the 100-mg group (72.1%\u201383.3% vs 68.9%). The frequency of AEs decreased with continued use of lasmiditan. Concomitant triptans and lasmiditan use did not increase AE frequency.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Based on high persistence and patient satisfaction rates, the 100-mg dose appears optimal for most patients. For those who adjusted dose levels, dose adjustments appeared beneficial to improve efficacy or tolerability, retaining patients on treatment. Collectively, the data suggest that patients who experienced efficacy continued to use lasmiditan regardless of the occurrence or frequency of AEs, and continued use appeared associated with fewer AEs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>European Union Drug Regulating Authorities Clinical Trials Database (EudraCT): 2018\u2013001661-17; ClinicalTrials.gov: NCT03670810; registration date: September 12, 2018.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s10194-024-01745-y","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T15:02:06Z","timestamp":1711378926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Mika","family":"Komori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akichika","family":"Ozeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Tanji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Kamiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Krege","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiho","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,25]]},"reference":[{"issue":"1","key":"1745_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z\u00a0(2020)  Lifting the Burden: the Global Campaign against Headache, Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21(1):137","journal-title":"J Headache Pain"},{"issue":"1","key":"1745_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s10194-023-01619-9","volume":"24","author":"L Fan","year":"2023","unstructured":"Fan L, Wu Y, Wei J, Xia F, Cai Y, Zhang S, Miao J, Zhou Y, Liu C, Yan W et al (2023) Global, regional, and national time trends in incidence for migraine, from 1990 to 2019: an age-period-cohort analysis for the GBD 2019. J Headache Pain 24(1):79","journal-title":"J Headache Pain"},{"issue":"1","key":"1745_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","volume":"23","author":"LJ Stovner","year":"2022","unstructured":"Stovner LJ, Hagen K, Linde M, Steiner TJ (2022) The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain 23(1):34","journal-title":"J Headache Pain"},{"key":"1745_CR4","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s42399-020-00390-1","volume":"2","author":"A Singh","year":"2020","unstructured":"Singh A, Gupta D, Sahoo AK (2020) Acute migraine: can the new drugs clinically outpace? SN Compr Clin Med 2:1132\u20131138","journal-title":"SN Compr Clin Med"},{"issue":"8","key":"1745_CR5","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/13543784.2023.2254691","volume":"32","author":"WD Wells-Gatnik","year":"2023","unstructured":"Wells-Gatnik WD, Wences Chirino TY, Onan FN, Onan D, Martelletti P (2023) Emerging experimental drugs in clinical trials for migraine: observations and key talking points. Expert Opin Investig Drugs 32(8):761\u2013771","journal-title":"Expert Opin Investig Drugs"},{"key":"1745_CR6","unstructured":"REYVOW\u00ae (lasmiditan) tablets package insert (2022). Eli Lilly and Company, Indianapolis, IN. http:\/\/pi.lilly.com\/us\/reyvow-uspi.pdf. Accessed 8 Nov 2023"},{"key":"1745_CR7","unstructured":"Food and Drug Administration (2019) FDA approves new treatment for patients with migraine. https:\/\/fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-patients-migraine. Accessed 8 Nov 2023"},{"issue":"7","key":"1745_CR8","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, Gaul C (2019) Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 142(7):1894\u20131904","journal-title":"Brain"},{"issue":"24","key":"1745_CR9","first-page":"e2222","volume":"91","author":"Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB, COL MIG-301 Study Group","year":"2018","unstructured":"Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB\u00a0(2018) COL MIG-301 Study Group Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology 91(24):e2222\u2013e2232","journal-title":"Neurology"},{"issue":"5","key":"1745_CR10","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/head.14122","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Takeshima T, Homma G, Tanji Y, Katagiri H, Komori M (2021) Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients. Headache 61(5):755\u2013765","journal-title":"Headache"},{"issue":"3","key":"1745_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/0333102421989232","volume":"41","author":"M Ashina","year":"2021","unstructured":"Ashina M, Reuter U, Smith T, Krikke-Workel J, Klise SR, Bragg S, Doty EG, Dowsett SA, Lin Q, Krege JH (2021) Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study. Cephalalgia 41(3):294\u2013304","journal-title":"Cephalalgia"},{"issue":"1","key":"1745_CR12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s10194-021-01343-2","volume":"22","author":"C Tassorelli","year":"2021","unstructured":"Tassorelli C, Bragg S, Krege JH, Doty EG, Ardayfio PA, Ruff D, Dowsett SA, Schwedt T (2021) Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine. J Headache Pain 22(1):132","journal-title":"J Headache Pain"},{"issue":"4","key":"1745_CR13","doi-asserted-by":"publisher","first-page":"333102423116174","DOI":"10.1177\/03331024231161745","volume":"43","author":"M Ashina","year":"2023","unstructured":"Ashina M, Roos C, Li LQ, Komori M, Ayer D, Ruff D, Krege JH (2023) Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial. Cephalalgia 43(4):3331024231161745","journal-title":"Cephalalgia"},{"key":"1745_CR14","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1):1\u2013211","DOI":"10.1177\/0333102417738202"},{"issue":"9","key":"1745_CR15","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/j.1526-4610.2001.01156.x","volume":"41","author":"RB Lipton","year":"2001","unstructured":"Lipton RB, Stewart WF, Sawyer J, Edmeads JG (2001) Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache 41(9):854\u2013861","journal-title":"Headache"},{"issue":"6 Suppl 1","key":"1745_CR16","first-page":"S20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J (2001) Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 56(6 Suppl 1):S20\u201328","journal-title":"Neurology"},{"issue":"3","key":"1745_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1046\/j.1526-4610.2000.00030.x","volume":"40","author":"BC Martin","year":"2000","unstructured":"Martin BC, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, Jhingran P (2000) Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1). Headache 40(3):204\u2013215","journal-title":"Headache"},{"issue":"7","key":"1745_CR18","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/WNL.0000000000001256","volume":"84","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC (2015) Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology 84(7):688\u2013695","journal-title":"Neurology"},{"key":"1745_CR19","doi-asserted-by":"crossref","unstructured":"Guy W (ed) (1976) Clinical global impression, ECDEU assessment manual for psychopharmacology \u2013 revised. US Department of Health, Education, and Welfare. National Institute of Mental Health, Rockville, MD","DOI":"10.1037\/e591322011-001"},{"key":"1745_CR20","unstructured":"R Core Team (2019) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria"},{"key":"1745_CR21","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.2147\/JPR.S399567","volume":"16","author":"S Kitamura","year":"2023","unstructured":"Kitamura S, Imai N, Tanji Y, Ozeki A, Komori M (2023) Lasmiditan in Japanese patients with common migraine comorbidities or concomitant medications: A post hoc safety and efficacy analysis from the MONONOFU study. J Pain Res 16:1725\u20131738","journal-title":"J Pain Res"},{"issue":"1","key":"1745_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-022-01440-w","volume":"23","author":"P Polavieja","year":"2022","unstructured":"Polavieja P, Belger M, Venkata SK, Wilhelm S, Johansson E (2022) Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings. J Headache Pain 23(1):76","journal-title":"J Headache Pain"},{"issue":"11","key":"1745_CR23","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1177\/0333102419864132","volume":"39","author":"JL Brandes","year":"2019","unstructured":"Brandes JL, Klise S, Krege JH, Case M, Khanna R, Vasudeva R, Raskin J, Pearlman EM, Kudrow D (2019) Interim results of a prospective, randomized, open-label, phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia 39(11):1343\u20131357","journal-title":"Cephalalgia"},{"issue":"3","key":"1745_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10194-011-0309-5","volume":"12","author":"P Tfelt-Hansen","year":"2011","unstructured":"Tfelt-Hansen P (2011) Optimal balance of efficacy and tolerability of oral triptans and telcagepant: a review and a clinical comment. J Headache Pain 12(3):275\u2013280","journal-title":"J Headache Pain"},{"key":"1745_CR25","unstructured":"REYVOW\u00ae tablets (lasmiditan) tablets package insert for Japan (2023) Eli Lilly and Company, Indianapolis, IN.\u00a0https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/530471_1190030F1024_1_03 (Japanese) Accessed 28 Nov 2023"},{"key":"1745_CR26","unstructured":"European Medicines Agency (2022) Rayvow. Lasmiditan.\u00a0https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rayvow. Accessed 15 Nov 2023"},{"issue":"1","key":"1745_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s10194-023-01678-y","volume":"24","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, Urman R, Gill K, Park AS, Vuvu F, Patel LB, Lu J, Wade RL, Frerichs L, Bensink ME (2023) Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway. J Headache Pain 24(1):153","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01745-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01745-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01745-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T15:02:29Z","timestamp":1711378949000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01745-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,25]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1745"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01745-y","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,25]]},"assertion":[{"value":"19 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out in accordance with the protocol, applicable local laws and regulations, and consensus principles derived from the International Conference on Harmonisation Good Clinical Practice guidelines, Declaration of Helsinki, and Council for International Organizations of Medical Sciences International Ethical Guidelines. The study protocol was approved by ethical review boards at each study site (full list previously published in Tassorelli et al., 2021 []). Written informed consent was obtained from all patients prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that medical writing and article processing costs were provided by Eli Lilly Japan K.K. and Daiichi Sankyo Company, Ltd.SS declares honoraria from Amgen K.K., Daiichi Sankyo Company Ltd, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co. Ltd.MS declares honoraria from Amgen Astellas BioPharma K.K., Daiichi Sankyo Company Ltd, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co. Ltd.TT declares research funding and collaborative research expenses from Biohaven, Ltd., Eisai Co., Eli Lilly Japan K.K., Ltd, Lundbeck Japan K.K., and Shionogi and Co., Ltd; honoraria from Amgen Astellas BioPharma K.K., Daiichi Sankyo Company Ltd, Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co. Ltd; and advisory roles for Hedgehog MedTech, Inc., Sawai Pharmaceutical Co., Ltd.JHK and LQL are employees and minor shareholders of Eli Lilly and Company.MK, AO, YT, and EK are employees of Eli Lilly Japan and minor shareholders of Eli Lilly and Company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}